Načítá se...
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Targeted cancer therapies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncogenic kinases. While these drugs have achieved some clinical success, the inactivation of kinase signaling via stimulation of endogenous phosphatases has received minimal attenti...
Uloženo v:
Vydáno v: | J Clin Invest |
---|---|
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
American Society for Clinical Investigation
2017
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5451217/ https://ncbi.nlm.nih.gov/pubmed/28504649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI89548 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|